Anavex Life Sciences Corp.
08/17/2026 | Press release | Distributed by Public on 08/17/2026 06:11
Anavex Life Sciences Mails Letter to Stockholders Reinforcing (Form 8-K)
Anavex Life Sciences Mails Letter to Stockholders Reinforcing
Relevant Experience of All Six Director Nominees
Launches VoteAnavex.com to Provide Additional Information on Anavex's Director Nominees
and How to Vote at the Annual Meeting of Stockholders
NEW YORK, NY, August 17, 2026 - Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system ("CNS") diseases with high unmet medical needs, today announced that the Executive Committee of the Anavex Board of Directors (the "Executive Committee") has mailed a letter to stockholders encouraging them to vote the WHITE proxy card "FOR" all six of Anavex's highly qualified directors standing for election at the Company's 2026 Annual Meeting of Stockholders (the "Annual Meeting").
The full text of the letter being mailed to stockholders has been filed with the U.S. Security and Exchange Commission (SEC) and is available at www.VoteAnavex.com along with voting instructions and other information about the Annual Meeting. The letter highlights the following six highly qualified, independent director nominees and the complementary skills and experience each nominee brings:
| ● | Dr. Jiong Ma, Ph.D. brings deep financial, transactional and capital markets expertise to the Board, with substantial experience investing in, partnering with and working with management teams to set strategy for disruptive technology and life sciences companies to shape the business, accelerate growth and drive long-term shareholder value. |
| ● | Dr. Peter Donhauser, D.O. brings critical, relevant experience to the Board as clinical expert leading research across numerous trials for some of the world's leading global pharmaceutical companies. |
| ● | Dr. Axel Paeger, M.D., MBA, MBI is a medically trained executive leader who brings deep experience in healthcare to the Board as founder of a leading healthcare provider in Europe. |
| ● | Gautam Patel, MBA (new independent candidate): The Executive Committee believes Mr. Patel is qualified to serve as a member of the Board because he brings extensive capital allocation, investment and financial advisory expertise to the Board, with a proven track record of executing growth-focused investments and guiding corporate strategy across the life sciences, financial services and technology sectors. |
| ● | Dr. Adrian Senderowicz, M.D. (new independent candidate): The Executive Committee believes Dr. Senderowicz is qualified to serve as a member of the Board because he brings deep drug development, clinical research and global regulatory expertise to the Board, with a proven track record of advancing novel therapeutics through critical international approvals to drive growth and long-term value. |
1
| ● | Dr. Claus van der Velden, Ph.D. brings accounting and executive financial experience to the Board that provides critical perspective on accounting and capital allocation strategy. |
The Annual Meeting will be held on September 24, 2026, and stockholders of record as of close of business on July 31, 2026 are entitled to vote.
If you have any questions or require any assistance with voting your shares, please call:
Innisfree M&A Incorporated
500 Fifth Avenue, 21st Floor
New York, NY 10110
Stockholders may call toll-free at (877) 750-0831
Brokers, banks and other nominees may call collect at (212) 750-5833
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders. Further information is available at www.anavex.com.
Anavex Life Sciences Corp. published this content on August 17, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on August 17, 2026 at 12:11 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]